| Primary Identifier | IPR034002 | Type | Domain |
| Short Name | TNFRSF8_N |
| description | Tumor necrosis factor receptor superfamily member 8 (TNFRSF8), also known as CD30, Ki-1 or D1S166E, is expressed by activated T and B cells. It transduces signals that lead to the activation of NF-kappaB, mediated by the adaptor proteins TRAF2 and TRAF5 []. This receptor has been shown to limit the proliferative potential of auto-reactive CD8 effector T cells and protect the body against autoimmunity []. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. CD30 is expressed in malignant Hodgkin and Reed-Sternberg cells on the surface of extracellular vesicles, facilitating CD30-CD30L interaction between cell types []. This receptor is also associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma, but not in seminoma, making it a useful marker in distinguishing between these germ cell tumors [, ]. Since CD30 has restricted expression in normal tissues, it is an optimal target for selectively eliminating CD30-expressing neoplastic cells by specific toxin-conjugated monoclonal antibodies (mAbs) [, ].This entry represents the N-terminal domain of TNFRSF8. TNF-receptors are modular proteins. The N-terminal extracellular part contains a cysteine-rich region responsible for ligand-binding. This region is composed of small modules of about 40 residues containing 6 conserved cysteines; the number and type of modules can vary in different members of the family [, , ]. |
